市場調查報告書
商品編碼
1084776

DNA修復藥的世界市場規模、佔有率、展望、機會分析 (2022年∼2028年):藥物 (Niraparib、Olaparib、Rucaparib、Talazoparib)、用途、流通管道、各地區

DNA Repair Drugs Market, by Drug (Niraparib, Olaparib, Rucaparib, Talazoparib, and Others), by Application by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 206 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

癌症的發生率增加,進入經營者的M&A,產品的銷售增加等要素促進全球DNA修復藥市場成長。還有為了強化產品系列的主要企業的無機策略也預期促進該市場的成長。

本報告提供全球DNA修復藥的市場調查,市場定義和概要,市場成長的各種影響因素分析,法律制度,市場規模的變化、預測,各種區分、各地區/主要國家的明細,競爭環境,主要企業簡介等彙整資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

第3章 市場動態、法律規章、趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 開發平台分析
  • 法規情境
  • 價格分析
  • PEST分析
  • 流行病學

第4章 全球DNA修復藥市場:各藥物類型

  • Niraparib(Zejula)
  • Olaparib(Lynparza)
  • Rucaparib(Rubraca)
  • Talazoparib(Talzenna)

第5章 全球DNA修復藥市場:各用途

  • 卵巢癌
  • 乳癌

第6章 全球DNA修復藥市場:各流通管道

  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球DNA修復藥市場:各地區

  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第8章 競爭情形

  • 企業簡介
    • AstraZeneca Plc.
    • Johnson &Johnson
    • GlaxoSmithKline plc.
    • Pfizer, Inc.
    • Clovis Oncology Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb
    • Merck KGaA
    • Genentech, Inc.
    • Artios Pharma
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • Karyopharm Therapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

第9章 Section

目錄
Product Code: CMI2617

DNA repair drugs such as Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna) are used for treating ovarian and breast cancer. These drugs fall under the category of Poly ADP-ribose Polymerase (PARP) inhibitors used as monotherapy in combination with other drugs for treatment of cancer.

Market Dynamics

Increasing incidences of cancer, increasing collaboration and acquisition with product launch by market players are major factors driving global DNA repair drugs market growth. In May 2019, AstraZeneca and Merck received the Health Canada approval for Lynparza as monotherapy maintenance treatment for patients with advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer.

Furthermore, inorganic strategies adopted by key players to enhance their product portfolio is expected to drive the market growth. In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II trials to evaluate rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometrioid ovarian cancer.

Key features of the study:

  • This report provides in-depth analysis of DNA repair drugs market and provides market size (US$ million) and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global DNA repair drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market

Detailed Segmentation:

  • Global DNA Repair Drugs Market, By Drug Type:
    • Niraparib (Zejula)
    • Olaparib (Lynparza)
    • Rucaparib (Rubraca)
    • Talazoparib (Talzenna)
  • Global DNA Repair Drugs Market, By Application:
    • Ovarian Cancer
    • Breast Cancer
  • Global DNA Repair Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global DNA Repair Drugs Market, By Region:
    • North America
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • AstraZeneca Plc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Johnson & Johnson
    • GlaxoSmithKline plc.
    • Pfizer, Inc.
    • Clovis Oncology Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb
    • Merck KGaA
    • Genentech, Inc.
    • Artios Pharma
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • Karyopharm Therapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Regulatory Scenario
  • Pricing Analysis
  • PEST Analysis
  • Epidemiology

4. Global DNA Repair Drugs Market, By Drug Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Niraparib (Zejula)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Olaparib (Lynparza)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Rucaparib (Rubraca)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Talazoparib (Talzenna)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

5. Global DNA Repair Drugs Market, By Application, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Ovarian Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global DNA Repair Drugs Market , By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global DNA Repair Drugs Market , By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Company Profiles
    • AstraZeneca Plc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Clovis Oncology Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AbbVie Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol Myers Squibb
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck KGaA
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Genentech, Inc.
    • Company Overview
    • Product Type Portfolio
    • Key Highlights
    • Market Strategies
    • Artios Pharma
    • Company Overview
    • Product Type Portfolio
    • Key Highlights
    • Market Strategies
    • Repare Therapeutics Inc.
    • Company Overview
    • Product Type Portfolio
    • Key Highlights
    • Market Strategies
    • Sierra Oncology, Inc.
    • Company Overview
    • Product Type Portfolio
    • Key Highlights
    • Market Strategies
    • Karyopharm Therapeutics Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ono Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact